Navigation Links
Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
Date:4/9/2008

- CDAS Expands Offering to Include Screening for Targeted Cancer Drugs

Using Genetically-Defined In-Vitro Human Disease Models -

HOPKINTON, Mass., April 9, 2008 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced a partnership with Horizon Discovery Ltd. (Cambridge, UK) that expands Caliper Discovery Alliances and Services' (CDAS) oncology cell line and screening capabilities for testing single drugs and combination therapies. Through this alliance, CDAS now offers unique, genetically-defined, and isogenic human cancer cell lines that allow researchers to better identify and characterize personalized drugs targeted at a specific subset of patients.

Isogenic cell-line pairs, where one cell line contains a genetic alteration or mutation of interest and the other contains the normal gene, represent cell-based models that accurately portray specific human diseases in the context of their matched normal genetic backgrounds. The inclusion of isogenic cell-line pairs in the discovery process enables scientists to better understand the mechanism of action of lead compounds, directly identify patient-relevant compounds from large compound libraries, re-profile existing drugs for new therapeutic indications, assess the efficacy of drug combinations, and identify potential side effects earlier in the discovery process.

"The alliance with Horizon Discovery adds significant value to existing CDAS offerings and illustrates Caliper's commitment to providing accurate in vitro and in vivo models for oncology research," said David Manyak, Executive Vice President of Drug Discovery Services, Caliper Life Sciences. "The addition of Horizon's isogenic cell lines to our existing oncology cell proliferation panel, and the ability to correlate results from these isogenic cell lines to efficacy in specific patient populations, further solidifies Caliper's in vitro-in vivo-human (IIH) bridge. Access to these tools will enable researchers to enhance the success rate and reduce the cost of discovering targeted monotherapy or combination therapies that better treat disease with fewer adverse events."

Rather than being a single disease, researchers now understand that there are numerous forms of cancer, many of which are associated with specific genetic alterations among cancer patient subpopulations. The discovery of targeted or personalized medicines that treat patients with a specific genetic makeup is a long and difficult process. Using more predictive cellular models that better reflect the complexity of biological systems will accelerate and rationalize many aspects of the discovery process -- including target selection, lead-compound generation and identification of the most responsive patients for clinical studies. The availability of such models also enables molecular diagnostic findings to be incorporated into existing drug discovery processes.

"Our extensive panel of isogenic human cancer cell-lines is a key, previously missing, tool in understanding the link between drug behavior and patients' genetic mutations. Our partnership with Caliper allows us to greatly expand the reach of our cell lines to assist researchers that are focused on uncovering cancer therapies," said Chris Torrance, CEO, Horizon Discovery. "Together we aim to significantly accelerate the search for new and more effective targeted or personalized drugs."

About Horizon Discovery

Horizon Discovery is a translational genomics company founded in June 2007 and is headquartered at the Babraham Research Campus, Cambridge, UK and with additional research laboratories in Torino, Italy. Horizon's goal is to convert new information on the genetic causes of cancer into laboratory models that will facilitate the discovery of drugs that target these defects. Central to this aim is Horizon Discovery's offering of isogenic cell-lines, which represent accurate models of defined cancer patient populations and their matched normal genetic backgrounds -- a missing link in the rational and efficient development of novel targeted anti-cancer agents. For more information, please visit http://www.horizondiscovery.com.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper is a registered trademark of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences Announces Date and Location of its 2008 Annual Meeting of Stockholders
2. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
3. Caliper Life Sciences to Present at Lehman Brothers Global Healthcare Conference
4. Caliper Life Sciences to Present at Cowen and Company 28th Annual Health Care Conference
5. Caliper Life Sciences Fourth Quarter 2007 Financial Results Conference Call Notice
6. Caliper Life Sciences to Present at Deutsche Bank 2008 Small and Mid Cap Growth Conference
7. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
8. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
9. Caliper Life Sciences Introduces Zephyr SPE Workstation to Improve Efficiency of Solid Phase Extraction
10. Caliper Life Sciences to Participate in Deutsche Banks Healthcare Technology Industry Day
11. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- The National Pharmaceutical Council (NPC) today announced that Ipsen ... as its newest member. David Cox , PhD, ... America ), will serve as his company,s representative ... to have Ipsen and Dr. Cox join NPC as ... welcome their insights in helping us identify and address ...
(Date:3/28/2017)... ... March 28, 2017 , ... LabKey and collaborator Just Biotherapeutics, ... solution, LabKey Biologics . Built in collaboration with Just and designed with ... provides drug research teams tools for biological entity registration, assay data integration, and ...
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: ... to report compelling safety and clinical data from its phase ... 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for ... ... a complete safety profile at 6 months and showed no ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis Corporation ... cancer, autoimmune disease and more through a single-cell precision engineering platform, today announced ... platform developed in the laboratory of Dr. James Heath at the California ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
Breaking Biology News(10 mins):